Physician profile
Gregory Wagner
NPI 1215342423
$3,096.21
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $535 · 2022: $1,612 · 2023: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $807.00 | 2021-2023 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $622.71 | 2021-2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $548.20 | 2021-2023 | Remicade, Simponi Aria, Stelara |
| Pfizer INC. | $161.00 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.70 | 2021-2023 | Entyvio |
| Gilead Sciences, INC. | $99.70 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $90.47 | 2022-2023 | |
| Celgene Corporation | $85.21 | 2021-2023 | Zeposia |
| Genzyme Corporation | $76.33 | 2022-2023 | |
| Boston Scientific Corporation | $65.47 | 2023 | |
| Exact Sciences Corporation | $63.86 | 2023 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $58.67 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $56.38 | 2022-2023 | Dificid |
| Redhill Biopharma INC. | $54.53 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Ironwood Pharmaceuticals, INC | $53.31 | 2022-2023 | Linzess |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $28.01 | 2021 | |
| Alnylam Pharmaceuticals INC. | $24.18 | 2022 | |
| Ardelyx, INC. | $23.18 | 2022 | |
| Sandoz INC. | $20.22 | 2023 | |
| Olympus America INC. | $16.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.